An exception provides high-dose intravenous methylprednisolone treatment in MS patients, that has been shown to reduce the portions CD4+ T cells expressing CD25 and CCR4 in the CSF within two weeks of treatment initiation [88]. Here, CCR4 is linked to myeloid sarcoma.